In addition, the currently developed inhibitors, such as PLX4720 and PLX4032, show limitations as they could not cure melanoma with both N-RAS and B-RAF mutations (Halaban et al., 2010; Kaplan et al., 2012). This evidence concerns the gene NRAS and melanoma.